Viral Suppression in the Setting of Multidrug Resistance to Nelfinavir, Tenofovir and Abacavir: A Case ReportAmy M Cheng1*, Rustin D Crutchley2, Meghann L Davis3, Carl Mayberry4 and Joseph C Gathe Jr.4
- *Corresponding Author:
- Amy Cheng
Department of Pharmacy Practice Temple University School of Pharmacy
Philadelphia, PA, 3307 N. Broad Street Philadelphia
PA 19140, USA
Tel: 1 (215) 707-6980
Fax: 1 (215) 707-8326
E-mail: [email protected]
Received date: March 30, 2017; Accepted date: April 05, 2017; Published date: April 12, 2017
Citation: Cheng AM, Crutchley RD, Davis ML, Mayberry C, Gathe Jr JC (2017) Viral Suppression in the Setting of Multidrug Resistance to Nelfinavir, Tenofovir and Abacavir: A Case Report. J AIDS Clin Res 8:683. doi:10.4172/2155-6113.1000683
Copyright: © 2017 Cheng AM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
One major barrier to achieving the primary goals of antiretroviral therapy is the development of drug resistance mutations to antiretroviral agents which render them less effective. For patients who are treatment experienced with many drug resistance mutations, selection of an effective antiretroviral regimen becomes challenging. We report a case of a 55 year old male on tenofovir, abacavir and nelfinavir with multiple resistance mutations to each of these agents, yet able to maintain viral suppression and high CD4 T cell counts. This patient was subsequently switched to protease inhibitor monotherapy for the management of HIV in the setting of multidrug resistance.